Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$14.06 - $27.29
Next Earnings Date
May 14 2025
Next Earnings Date
May 14 2025
Latest price
Market Cap | $1.90B |
EV | $1.06B |
Shares Outstanding | 118.66M |
Beta | -0.00 |
Analyst Rating | BUY |
Analyst Target Price | $46.89 |
P/E 2025E | - |
P/Revenue 2025E | 104.83x |
Revenue | - |
EPS | 4.30% |
Operating Cash Flow | -74.30% |
Free Cash Flow | -114.80% |
Revenue | 40.20% |
EPS | 13.90% |
Operating Cash Flow | 1.10% |
Free Cash Flow | 57.70% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -1193.70% |
ROE 2025E | - |
ROCE 2024 | -46.20% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
NewAmsterdam Pharma Company N.V.
NAMS
Sector
Healthcare
Industry
Biotechnology
CEO
Davidson, Michael
Employees
68
Website
www.newamsterdampharma.comIPO Date
2021-02-09
Headquarters
Gooimeer 2-35, Naarden, Noord-Holland, 1411 DC, Netherlands
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved